The Life Sciences Collection spans markets that are central to the life and wellbeing of the more than 7.5 billion people on our planet. From emerging diagnostics, to brand new therapies and treatment technologies, our expert analysts know where your focus – and investment – should be when it comes to biotechnology, pharmaceuticals and healthcare. As your senior editor, I look forward to introducing you to new opportunities.
These reports emphasize markets where technologies intersect with the building blocks of human life, including DNA, RNA, cancer, genomics, genetics, molecular diagnostics and more.
Globally, healthcare constitutes a multi trillion-dollar industry. Reports in this category span the range of treatments, administration practices and technologies available around the world.
Enormously important intersection of engineering, tissue manipulation, the surgeons scalpel and design. Specialist companies target well known and also the barely pronounceable conditions.
770 Reports in Life Sciences
This report provides a brief description of advanced image-guided surgery (IGS) systems, also known as surgical navigation, and their applications in medicine and dentistry. Recent innovations and current and emerging trends in IGS technology will also be assessed.
The global market for DNA read, write and edit applications should grow from $17.0 billion in 2019 to $43.1 billion by 2024 with a compound annual growth rate (CAGR) of 20.5% during the period of 2019-2024.
The report provides a detailed description of Machine learning (ML) as the branch of artificial intelligence and its possible range of functions. Latest developments and recent achievements in the life sciences due to machine learning will also be assessed.
This report provides a brief description of super-resolution imaging techniques, and evaluates the current and emerging trends related to this technology.
The global market for medical device should grow from $470.5 billion in 2018 to reach $640.9 billion by 2023 at a compound annual growth rate (CAGR) of 6.4% for the period of 2018-2023.
The global market for pharmacy automation should grow from $5.1 billion in 2019 to $7.8 billion by 2024 at a compound annual growth rate (CAGR) of 8.6% for the period of 2019-2024.
The global market for human identification reached $43.0 billion in 2019 and should reach $83.9 billion by 2024, at a compound annual growth rate (CAGR) of 14.3% for the period of 2019-2024.
Consumption of nanostructures in the life science sectors (e.g., nanoparticles, nanospheres, nanocapsules, and quantum dots) is projected to be characterized by healthy growth during the next five years. The report provides a detailed description of applications in the medical sector and examines main drivers for market growth within this industry. The global market for nanostructures in life science should reach $17.8 billion in 2019 and is projected to reach $33.8 billion in 2024, registering a CAGR of 13.7% during the five-year period.
The global market for communicable disease should grow from $57.7 billion in 2019 to $69.4 billion by 2024 at a compound annual growth rate (CAGR) of 3.8% for the period of 2019-2024.
This report presents a perspective on the adoption of continuous manufacturing technologies by pharmaceuticals, the role of the FDA and implications for the generics sector.
The global market for organ-on-a-chip should grow from $11.3 billion in 2018 to $60.6 billion by 2023 at a compound annual growth rate (CAGR) of 39.9% from 2018 to 2023.
The global single-use technology in the biopharmaceutical market should reach $5.9 billion by 2024 from $3.5 billion in 2019 at a compound annual growth rate (CAGR) of 11.3% for the period of 2019 to 2024.
The global market for point of care (POC) diagnostics and testing should grow from $19.3 billion in 2018 to $25.5 billion by 2023 with a compound annual growth rate (CAGR) of 5.7% from 2018 to 2023.
The global market for neurology should grow from $33.3 billion in 2019 to $39.4 billion by 2024 at a compound annual growth rate (CAGR) of 3.5% for the period of 2019-2024.
5G wireless in healthcare—products such as wireless medical devices, electronic health records (EHR) and remote surgical equipment. In addition, pharmaceutical companies are harvesting Big Data from wireless applications to make drug development and clinical testing more efficient
This report will assess the latest developments that are taking place with regard to the current research and development environment of TILs and explore the novel strategies companies are adopting to identify and enhance TIL selection, biosynthesis and delivery in a wide range of metastatic cancers including, melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors.
The global market for catheters should grow from $27.2 billion in 2018 to $34.5 billion by 2023 at a compound annual growth rate (CAGR) of 4.8% for the period of 2018-2023.
The global market for GxP/GMP regulation testing services should grow from $8.1 billion in 2019 to reach $14.2 billion by 2024 at a compound annual growth rate (CAGR) of 11.8% for the period of 2019-2024.
The global stem cell and regenerative medicines market should grow from $21.8 billion in 2019 to reach $55.0 billion by 2024 at a compound annual growth rate (CAGR) of 20.4% for the period of 2019-2024.
Just in 2017, medical cannabis totaled $7.3 billion, up from $4.8 billion in 2016. This segment will likely achieve a 22.2% CAGR to reach nearly $19.8 billion at the producer level in 2022 and will account to more than 80% of the global market. Politics aside, one must remember that marijuana is still a drug and needs to be treated as such with its potential side effects. Even if cannabinoids-based drugs will not fully substitute opioid use, combination of medical marijuana use with reduced dose of opioid will help to curb the crisis.
The global market for sensors should grow from $173.4 billion in 2019 to reach $323.3 billion by 2024 at a compound annual growth rate (CAGR) of 13.3% for the period of 2019-2024.
The global market for microbiome sequencing should grow from $885 million in 2018 to $2.0 billion by 2023 at a compound annual growth rate (CAGR) of 18.2% for the period of 2018-2023.
The global market for liquid biopsy should grow from $2.3 billion in 2018 to reach $6.1 billion by 2023 at a compound annual growth rate (CAGR) of 21.1% for the period of 2018-2023.
The report provides a detailed description of autoimmune responses and possible ways that drug development can augment immune responses so as to improve antitumor activity and reduce off target effect.This report will assess the latest developments in the IL-2 research and development and explore the novel strategies companies are adopting to augment immune response and avoid off target effects in a wide range of conditions including, metastatic melanoma (MM), renal cell carcinoma (RCC), urothelial cancers (US) relapse remitting multiple sclerosis (RRMS), Type 1 diabetes (T1D), as a prophylaxis post-transplant and allergic conditions.What's coming: There are more than 200 studies underway evaluating IL-2 based therapies either as a monotherapy or in combination. The key products and companies that we believe are worth watching in this space are summarized.
The global market for tissue engineering and regeneration should grow from $24.7 billion in 2018 to $109.9 billion by 2023 with a compound annual growth rate (CAGR) of 34.8% from 2018 to 2023.
6 Upcoming Reports in Life Sciences
This report provides an overview of the current and future characteristics of the global market for viral vector and plasmid DNA technologies. The key objective of the report is to analyze the present and future opportunities and major factors influencing this market.
Access digital pathology market research and industry analysis on market size, applications, forecasts, company profiles, and patents.
- Information on the top potential drug launches by pharma companies in 2019
- Knowledge about drug, mechanism of action, and briefing of clinical evidences
- Detailed information and insights on the drug Upadacitinib which is manufactured by AbbVie Inc. , Ultomiris (ravulizumab-cwvz) a humanized monoclonal antibody manufactured by Alexion Pharmaceuticals Inc. and many more
- Insights into regulatory approvals, market scope, and analysis of pipeline molecules
- Detailed profiles of the companies and competitors related to the industry
Get a comprehensive overview of the global market for medical wearables beyond FitBit and how these medical wearables devices monitor blood sugar, glucose, and chronic diseases like heart diseases, diabetes, and various other parameters.
This report provides a general overview of the surgical devices global markets and discusses the prospective growth opportunities. The coverage provides a focused view and articulates the challenges that need to be addressed to succeed in the global market.
This report assesses the latest developments in breath biopsy research and analysis and explores the novel approaches that companies are adopting to identify and enhance breath biopsy in drug development, diagnosis and treatment of respiratory diseases, cancer, metabolic disorders and CNS diseases.
PCR for POC Diagnostics
BCC Research analyst Todd Graham delves into the markets being served by the new technology for polymerase chain reaction for point-of-care diagnostics, sharing the uses, outlook, and more on these clinical diagnostic kits. Recorded live on May 16, 2018.
How to Dissect a Market Opportunity
BCC Research Senior Editor Gordon Nameni shares how to interpret market research to uncover market opportunities at a live event on September 12, 2017, in Boston, MA.